Cargando…

A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications

BACKGROUND: Allogeneic mesenchymal stromal cells (MSCs) have been used extensively in various clinical trials. Nevertheless, there are concerns about their efficacy, attributed mainly to the heterogeneity of the applied populations. Therefore, producing a consistent population of MSCs is crucial to...

Descripción completa

Detalles Bibliográficos
Autores principales: Pakzad, Mohammad, Hassani, Seyedeh Nafiseh, Abbasi, Fatemeh, Hajizadeh-Saffar, Ensiyeh, Taghiyar, Leila, Fallah, Nasrin, Haghparast, Newsha, Samadian, Azam, Ganjibakhsh, Meysam, Dominici, Massimo, Baharvand, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852915/
https://www.ncbi.nlm.nih.gov/pubmed/35175538
http://dx.doi.org/10.1007/s12015-022-10351-x
_version_ 1784653128164966400
author Pakzad, Mohammad
Hassani, Seyedeh Nafiseh
Abbasi, Fatemeh
Hajizadeh-Saffar, Ensiyeh
Taghiyar, Leila
Fallah, Nasrin
Haghparast, Newsha
Samadian, Azam
Ganjibakhsh, Meysam
Dominici, Massimo
Baharvand, Hossein
author_facet Pakzad, Mohammad
Hassani, Seyedeh Nafiseh
Abbasi, Fatemeh
Hajizadeh-Saffar, Ensiyeh
Taghiyar, Leila
Fallah, Nasrin
Haghparast, Newsha
Samadian, Azam
Ganjibakhsh, Meysam
Dominici, Massimo
Baharvand, Hossein
author_sort Pakzad, Mohammad
collection PubMed
description BACKGROUND: Allogeneic mesenchymal stromal cells (MSCs) have been used extensively in various clinical trials. Nevertheless, there are concerns about their efficacy, attributed mainly to the heterogeneity of the applied populations. Therefore, producing a consistent population of MSCs is crucial to improve their therapeutic efficacy. This study presents a good manufacturing practice (GMP)-compatible and cost-effective protocol for manufacturing, banking, and lot-release of a homogeneous population of human bone marrow-derived clonal MSCs (cMSCs). METHODS: Here, cMSCs were isolated based on the subfractionation culturing method. Afterward, isolated clones that could reproduce up to passage three were stored as the seed stock. To select proliferative clones, we used an innovative, cost-effective screening strategy based on lengthy serial passaging. Finally, the selected clones re-cultured from the seed stock to establish the following four-tired cell banking system: initial, master, working, and end of product cell banks (ICB, MCB, WCB, and EoPCB). RESULTS: Through a rigorous screening strategy, three clones were selected from a total of 21 clones that were stored during the clonal isolation process. The selected clones met the identity, quality, and safety assessments criteria. The validated clones were stored in the four-tiered cell bank system under GMP conditions, and certificates of analysis were provided for the three-individual ready-to-release batches. Finally, a stability study validated the EoPCB, release, and transport process of the frozen final products. CONCLUSION: Collectively, this study presents a technical and translational overview of a GMP-compatible cMSCs manufacturing technology that could lead to the development of similar products for potential therapeutic applications. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12015-022-10351-x.
format Online
Article
Text
id pubmed-8852915
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-88529152022-02-18 A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications Pakzad, Mohammad Hassani, Seyedeh Nafiseh Abbasi, Fatemeh Hajizadeh-Saffar, Ensiyeh Taghiyar, Leila Fallah, Nasrin Haghparast, Newsha Samadian, Azam Ganjibakhsh, Meysam Dominici, Massimo Baharvand, Hossein Stem Cell Rev Rep Article BACKGROUND: Allogeneic mesenchymal stromal cells (MSCs) have been used extensively in various clinical trials. Nevertheless, there are concerns about their efficacy, attributed mainly to the heterogeneity of the applied populations. Therefore, producing a consistent population of MSCs is crucial to improve their therapeutic efficacy. This study presents a good manufacturing practice (GMP)-compatible and cost-effective protocol for manufacturing, banking, and lot-release of a homogeneous population of human bone marrow-derived clonal MSCs (cMSCs). METHODS: Here, cMSCs were isolated based on the subfractionation culturing method. Afterward, isolated clones that could reproduce up to passage three were stored as the seed stock. To select proliferative clones, we used an innovative, cost-effective screening strategy based on lengthy serial passaging. Finally, the selected clones re-cultured from the seed stock to establish the following four-tired cell banking system: initial, master, working, and end of product cell banks (ICB, MCB, WCB, and EoPCB). RESULTS: Through a rigorous screening strategy, three clones were selected from a total of 21 clones that were stored during the clonal isolation process. The selected clones met the identity, quality, and safety assessments criteria. The validated clones were stored in the four-tiered cell bank system under GMP conditions, and certificates of analysis were provided for the three-individual ready-to-release batches. Finally, a stability study validated the EoPCB, release, and transport process of the frozen final products. CONCLUSION: Collectively, this study presents a technical and translational overview of a GMP-compatible cMSCs manufacturing technology that could lead to the development of similar products for potential therapeutic applications. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12015-022-10351-x. Springer US 2022-02-17 2022 /pmc/articles/PMC8852915/ /pubmed/35175538 http://dx.doi.org/10.1007/s12015-022-10351-x Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Pakzad, Mohammad
Hassani, Seyedeh Nafiseh
Abbasi, Fatemeh
Hajizadeh-Saffar, Ensiyeh
Taghiyar, Leila
Fallah, Nasrin
Haghparast, Newsha
Samadian, Azam
Ganjibakhsh, Meysam
Dominici, Massimo
Baharvand, Hossein
A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications
title A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications
title_full A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications
title_fullStr A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications
title_full_unstemmed A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications
title_short A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications
title_sort roadmap for the production of a gmp-compatible cell bank of allogeneic bone marrow-derived clonal mesenchymal stromal cells for cell therapy applications
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852915/
https://www.ncbi.nlm.nih.gov/pubmed/35175538
http://dx.doi.org/10.1007/s12015-022-10351-x
work_keys_str_mv AT pakzadmohammad aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT hassaniseyedehnafiseh aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT abbasifatemeh aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT hajizadehsaffarensiyeh aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT taghiyarleila aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT fallahnasrin aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT haghparastnewsha aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT samadianazam aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT ganjibakhshmeysam aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT dominicimassimo aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT baharvandhossein aroadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT pakzadmohammad roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT hassaniseyedehnafiseh roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT abbasifatemeh roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT hajizadehsaffarensiyeh roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT taghiyarleila roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT fallahnasrin roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT haghparastnewsha roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT samadianazam roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT ganjibakhshmeysam roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT dominicimassimo roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications
AT baharvandhossein roadmapfortheproductionofagmpcompatiblecellbankofallogeneicbonemarrowderivedclonalmesenchymalstromalcellsforcelltherapyapplications